Literature DB >> 27802491

Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides.

Satyakam Bhagavati1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27802491     DOI： 10.1001/jamaneurol.2016.4332

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  4 in total

1.  Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.

Authors:  Yusuke Echigoya; Kenji Rowel Q Lim; Nhu Trieu; Bo Bao; Bailey Miskew Nichols; Maria Candida Vila; James S Novak; Yuko Hara; Joshua Lee; Aleksander Touznik; Kamel Mamchaoui; Yoshitsugu Aoki; Shin'ichi Takeda; Kanneboyina Nagaraju; Vincent Mouly; Rika Maruyama; William Duddy; Toshifumi Yokota
Journal:  Mol Ther       Date:  2017-07-28       Impact factor: 11.454

2.  Use of a Self-Delivering Anti-CCL3 FANA Oligonucleotide as an Innovative Approach to Target Inflammation after Spinal Cord Injury.

Authors:  Nicolas Pelisch; Jose Rosas Almanza; Kyle E Stehlik; Brandy V Aperi; Antje Kroner
Journal:  eNeuro       Date:  2021-03-11

3.  Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression.

Authors:  Yanjie Li; Jixue Li; Jun Wang; David R Lynch; Xiulong Shen; David R Corey; Darshan Parekh; Balkrishen Bhat; Caroline Woo; Jonathan J Cherry; Jill S Napierala; Marek Napierala
Journal:  Nucleic Acids Res       Date:  2021-11-18       Impact factor: 16.971

Review 4.  Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.

Authors:  Ashok Verma
Journal:  Ann Indian Acad Neurol       Date:  2018 Jan-Mar       Impact factor: 1.383
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.